Core Insights - In 2025, Beijing's industrial added value above designated size increased by 6.5% year-on-year in real terms [1] Industry Performance - The computer, communication, and other electronic equipment manufacturing sectors grew by 20.2% and 17.7% respectively, driven by new energy vehicles, consumer electronics, and integrated circuits [1] - The electricity and heat production and supply industry saw a growth of 5.5% [1] - The pharmaceutical manufacturing sector experienced a decline of 8.6% [1] - The five major equipment manufacturing industries grew by 4.9% [1] Export Performance - The value of industrial exports above designated size reached 211.34 billion yuan, marking a growth of 6.4% [1] - The automotive manufacturing and specialized equipment manufacturing sectors grew by 24.6% and 10.8% respectively [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 一、召开会议的基本情况 （一）股东会届次：2026年第一次临时股东会 （二）股东会的召集人：董事会 金陵药业股份有限公司 （四）会议时间： 1、现场会议时间：2026年2月5日14:30 关于召开2026年第一次临时股东会的通知 （三）本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 证券代码：000919 证券简称：金陵药业 公告编号：2026-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 ■ 2、网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2026年2月5日9:15-9:25，9:30- 11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2026年2月5日9:15至15:00 的任意时间。 （五）会议的召开方式：现场表决与网络投票相结合。 （六）会议的股权登记日：2026年1月30日 ...

Group 1: New Stock Subscription - The new stock available for subscription today is Meidele, which focuses on the research, design, manufacturing, and sales of intelligent manufacturing equipment, particularly modular conveyor systems and industrial components [2][5] - Meidele's products are integrated with smart production equipment and are widely used in industries such as new energy, automotive parts, electronics, and logistics [2] - Major clients include leading companies in the industry such as BYD, CATL, and Xinzhi Group [2] Group 2: Financial Performance of Meidele - Meidele's projected revenues for 2022, 2023, and 2024 are 1.031 billion, 1.009 billion, and 1.138 billion yuan respectively, with net profits of 222.5 million, 205.2 million, and 210.8 million yuan [2] - For 2025, Meidele expects revenues between 1.3 billion and 1.4 billion yuan, representing a year-on-year growth of 14.26% to 23.05%, and net profits between 270 million and 300 million yuan, indicating a growth of 28.11% to 42.34% [2] Group 3: New Stock Listing - The new stock listed today is Aisheren, which is the largest manufacturer of medical care pads in China and a leading exporter of medical dressings [2][6] - Aisheren's projected revenues for 2022, 2023, and 2024 are 573.6 million, 574.7 million, and 691.6 million yuan respectively, with net profits of 62.8 million, 66.96 million, and 80.71 million yuan [3] - The company has a total market value of 1.082 billion yuan and is underwritten by Dongwu Securities [6]

（文章来源：证券日报） 证券日报网讯 1月20日，欧康医药发布公告称，公司于近日收到由四川省科学技术厅、四川省经济和信 息化厅、四川省财政厅、国家税务总局四川省税务局联合颁发的《高新技术企业证书》，证书编号： GR202551003919，有效期：三年。本次系公司持有的原高新技术企业证书有效期届满后进行的重新认 定。 ...

Important Events - Yidian Tianxia has resumed trading after the suspension for verification [1] - Jianghuai Microelectronics will have its actual controller changed to Shanghai State-owned Assets Supervision and Administration Commission, and its stock has resumed trading [1] - Huas Technology's actual controller has changed to Zheng Jianbo, and its stock has resumed trading [1] - Yingfang Microelectronics plans to acquire 100% shares of Shanghai Xiaokeli and Fujide China, which is expected to constitute a major asset restructuring, and its stock has resumed trading [1] - Hualing Cable has terminated the acquisition of Xingxin Aerospace's controlling stake, which provides supporting products for Shenzhou series spacecraft, Chang'e series detectors, and various launch vehicles [1] - Rongsheng Development's subsidiary plans to acquire 100% equity of Yingde Jihong and Yingde Jiyue for 40 million yuan [1] - Donghua Software plans to establish a wholly-owned subsidiary, Donghua Zhizhi, with an investment of 300 million yuan [1] - Zhongwei Semiconductor is about to launch its first non-volatile memory chip [1] - Xingqi Eye Medicine's SQ-24071 eye drops have received clinical trial approval [1] Contracts & Project Bids - Pingzhi Information has pre-qualified for an intelligent computing service project worth approximately 489 million yuan [1] - Nanshan Aluminum plans to invest 437 million USD to build a 250,000-ton annual electrolytic aluminum project in Indonesia [1] - Yian Technology's controlling company has signed a project entry contract to create a benchmark project for high-quality amorphous alloy (liquid metal) [1] - Jiangxi Copper has signed a three-year cooperation framework agreement with the Ordnance Material Department, expecting to sell 9.7 billion yuan worth of copper rods and other products annually [1] - Wutong Holdings' wholly-owned subsidiary did not win the bid for the Agricultural Bank of China mobile SMS long number agency service project, which is expected to have a significant adverse impact on the company's future operating performance [1] Operations & Performance - Hunan Yuneng expects a net profit increase of 94%-136% year-on-year in 2025, driven by a rebound in lithium carbonate prices enhancing overall profitability [1] - Jilin Carbon Valley anticipates a net profit increase of 92.81%-135.66% year-on-year in 2025 [1] - Fulai Anticipates a net profit increase of 81.67%-127.08% year-on-year in 2025 [1] - Dingtong Technology expects a net profit increase of 120% year-on-year in 2025, with significant growth in high-speed communication product business [1] - Chengdu Huamei anticipates a net profit increase of 74%-109% year-on-year in 2025, with Q4 net profit expected to grow by 458%-614% quarter-on-quarter [1] - Anfu Technology expects a net profit increase of 28.55%-50.91% year-on-year in 2025 [1] - Dinglong Co. anticipates a net profit increase of 34.44%-40.20% year-on-year in 2025 [1] - Mingtai Aluminum expects a net profit increase of 12%-14% year-on-year in 2025 [1] - Huace Testing anticipates a net profit increase of 10%-11% year-on-year in 2025 [1] - Xianglu Tungsten Industry expects a net profit of 125 million to 180 million yuan in 2025, with tungsten metal raw material prices continuing to rise throughout the year [1] Financing & Capital Increase - Jiangxi Copper plans to register and issue debt financing instruments not exceeding 25 billion yuan [2] - Goldwind Technology has terminated the public REITs application and issuance work [2] - Huichuan Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange [2]

Economic Growth - In Q4 2025, China's GDP grew by 4.5% year-on-year, aligning with market expectations, achieving a full-year GDP growth of 5.0%[2] - The contribution rates of final consumption expenditure, gross capital formation, and net exports to GDP changed from 44.5%, 25.2%, and 30.3% in 2024 to 52.0%, 15.3%, and 32.7% in 2025, respectively[2] Consumption and Investment - Final consumption expenditure's contribution to economic growth exceeded 50% due to the "trade-in" policy, with retail sales growth rising from 3.5% in 2024 to 3.7% in 2025[2] - Fixed asset investment decreased by 3.8% year-on-year in 2025, which indirectly boosted the contribution of final consumption to economic growth[2] Industrial Performance - Industrial value-added growth in December 2025 rose to 5.2% from 4.8% in November, while the service production index increased from 4.2% to 5.0%[2] - High-tech industry value-added growth reached 11.0% in December 2025, marking the highest level for the year, with an annual growth of 9.4% compared to 8.9% in 2024[2] Capacity Utilization and Real Estate - China's industrial capacity utilization rate increased from 74.6% in Q3 2025 to 74.9% in Q4 2025, but was down 1.3 percentage points year-on-year, the largest decline since Q2 2023[2] - Real estate indicators showed a narrowing decline, with property sales area and value improving from -17.0% and -24.6% in November to -15.5% and -23.5% in December 2025[3] Policy Outlook - The report suggests that structural highlights in the economy are emerging, but the "strong supply, weak demand" situation persists, necessitating continued policy support[3] - The central bank's structural interest rate cuts and expanded lending in January 2026 indicate a clear intention for a more accommodative credit policy to stimulate economic growth[3]

Group 1 - Jia Yin Technology (874629) announced an adjustment to its listing plan due to current operational conditions and future strategic planning, with the termination of guidance confirmed by Ningbo Securities Regulatory Bureau on January 19, 2026 [1] - The company was established in 2001 and specializes in the research, production, and sales of various pump products, valve products, sensors, and other core components for small household appliances [3] - For the first half of 2025, the company reported operating revenue of 486.71 million yuan, a year-on-year increase of 46.93%, while net profit attributable to shareholders decreased by 9.23% to 29.53 million yuan [4] Group 2 - Another company, Yipuno Kang (835852), also announced the termination of its listing guidance due to its own strategic planning needs, confirmed by Anhui Securities Regulatory Bureau on January 16, 2026 [5] - Yipuno Kang, established in 2012, focuses on the research, production, and sales of in vitro diagnostic products, reporting a 30.08% decline in operating revenue to 72.64 million yuan for the first half of 2025 [7] - The company experienced a significant net loss of 8.12 million yuan, a decrease of 261.09% compared to the previous year, with a high accounts receivable balance of 99.40 million yuan, accounting for 27.44% of total assets [9]

Company Overview - Zhan Yan Biotechnology Co., Ltd. was established on December 6, 2019, with a registered capital of 61.62 million yuan and is located in Chengdu, Sichuan, China [1] - The company is primarily engaged in the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The controlling shareholder is Zhang Yingting, who directly holds 62.1551% of the company's shares [1] IPO and Financial Performance - Zhan Yan Biotechnology has completed its IPO counseling registration with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange [1] - The company aims to be listed on the New Third Board by September 2025 [1] - Projected revenues for 2023 and 2024 are 486 million yuan and 597 million yuan, respectively, with net profits of 68.48 million yuan and 73.50 million yuan [2][3] - The gross profit margins for 2023 and 2024 are expected to be 62.33% and 68.34%, respectively [2][3] Shareholding Structure - As of the date of the public transfer prospectus, Zhang Yingting directly holds 62.16% of the shares and, through concerted actions, controls 91.22% of the voting rights [3] - Other shareholders include Yang Fengle, who holds 17.79%, and Hengqin Zhan Yan, an employee stock ownership platform, which holds 11.28% [3] - Wang Kun directly holds 4.06% and indirectly holds 0.24%, while Tax Ke Ying directly holds 0.41% and indirectly holds 0.31% [4] Management Team - Zhang Yingting serves as the Chairman and Manager of the company [5] - Wang Kun is the Director and Deputy Manager, while Tax Ke Ying is the Secretary of the Board and Chief Financial Officer [5] - The management team has extensive experience in the pharmaceutical and biotechnology sectors, with backgrounds in various companies prior to joining Zhan Yan Biotechnology [6][7][8]

IPO and Financing Overview - A total of 6 companies are scheduled for IPO review next week (January 19-23), aiming to raise a combined total of 4.884 billion yuan [1][2]. Company Summaries Atech - Atech is a leading provider of automotive electronic intelligent solutions, focusing on the development, production, and sales of automotive electronic products across various domains [7][8]. - The company plans to issue up to 44,772,665 shares, with a total capital raised not exceeding 150 million yuan [10]. Lichi Intelligent - Lichi Intelligent specializes in automated material handling systems, providing comprehensive solutions for industries such as lithium battery manufacturing and fine chemicals [11][12]. - The company aims to issue between 40,762,223 and 45,857,500 shares, depending on the exercise of the over-allotment option [12]. Baierji - Baierji focuses on the research, production, and sales of biomedical materials, aiming to provide safe and effective products for medical applications [17][18]. - The company plans to issue up to 9.2072 million shares, with a total capital raised not exceeding 10.5931 million yuan [19][21]. Huikang Technology - Huikang Technology is engaged in the research, production, and sales of refrigeration equipment, including ice machines and refrigerators, primarily serving both consumer and commercial markets [23][24]. - The company plans to issue up to 37,087,858 shares, with a total capital raised not exceeding 45.11357 million yuan [24][25]. Mifutech - Mifutech specializes in the development and production of key components for automotive fluid systems and other plastic parts, applicable in both traditional and new energy vehicles [27][28]. - The company plans to issue 19,532,984 shares, with a total capital raised not exceeding 22,462,931 yuan [29][30]. Toptech - Toptech focuses on the research, production, and sales of intelligent controllers and products, serving various sectors including consumer electronics and industrial automation [32][33]. - The company plans to issue up to 11,558,970 shares, with a total capital raised not exceeding 13,292,816 yuan [33][35].

通过天眼查大数据分析，上海新耀湃科医疗科技股份有限公司共对外投资了2家企业，知识产权方面有 商标信息31条，专利信息54条，此外企业还拥有行政许可10个。 天眼查信息显示，上海新耀湃科医疗科技股份有限公司的股东为：上海新耀枫榕企业管理合伙企业（有 限合伙）、黄琳霖、上海新耀疆域企业管理合伙企业（有限合伙）。 1月15日，天眼查融资历程显示，上海新耀湃科医疗科技股份有限公司近日获得"B+轮"融资，涉及融资 金额约亿人民币，投资机构为新耀湃科完成亿元B+轮融资，加速迈向全球高端给药装置领军企业！。 资料显示，上海新耀湃科医疗科技股份有限公司法定代表人为何玉锋，成立于2021年，位于上海市，是 一家以从事医药制造业为主的企业。企业注册资本957.6024万人民币，并已于2026年完成了B+轮，交易 金额约亿人民币。 来源：市场资讯 ...